PATENT CLAIM ANALYSIS

Application Number: 15916617
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["424", "400000"]

Abstract:
The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding agent to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function.

Claim (Index 11):
The method of any one of  claims 1  to  7  wherein the crosslinked cation exchange polymer comprising structural units corresponding to Formulae 1, 2, and 3, wherein\n (i) the structural units corresponding to Formula 1 constitute at least about 85 wt. % based on the total weight of structural units of Formulae 1, 2, and 3 in the polymer, calculated from the amounts of monomers used in the polymerization reaction, and the weight ratio of the structural unit corresponding to Formula 2 to the structural unit corresponding to Formula 3 is from about 4:1 to about 1:4, or \n (ii) the mole fraction of the structural unit of Formula 1 in the polymer is at least about 0.87 based on the total number of moles of the structural units of Formulae 1, 2, and 3, calculated from the amounts of monomers used in the polymerization reaction, and the mole ratio of the structural unit of Formula 2 to the structural unit of Formula 3 is from about 0.2:1 to about 7:1, and \n Formula 1, Formula 2, and Formula 3 correspond to the following structures: \n wherein\n R 1  and R 2  are independently hydrogen, alkyl, cycloalkyl, or aryl; \n A 1  is carboxylic, phosphonic, or phosphoric, in its salt or acid form; \n X 1  is arylene; \n X 2  is alkylene, an ether moiety or an amide moiety.

Metadata:
- Claim Count in Document: 87.0
- Percentile: 90.0
- Lexical Diversity: 2.39062
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14581698', '15287179', '15052193', '15052186', '15472936']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7613143794542555
- 35 USC 102 Novelty (BERT): 0.6177446496395467
- Combined Prediction Score: 0.7469574064727846
- Mean Citation Score: 433.907818
- Max Citation Score: 690.2378
- Similarity Product: 486.867982770896

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test